Main Menu

EPHOS-B

Effect of perioperative anti-HER2 therapy on early breast cancer study – biological phase.

Disease site: Breast cancer

Treatment modality: Systemic therapy

Status: In follow up

Trial details

EPHOS-B is a phase III, multicentre, three group, randomised controlled trial to determine whether pre-operative treatment of HER2+ breast cancer patients with anti-HER2 therapy inhibits proliferation or increases apoptosis.

Part 1 of EPHOS-B closed to recruitment in August 2013. In this part of the study, HER2+ patients received either perioperative trastuzumab, perioperative lapatinib, or standard care. Part 2 immediately superseded part 1, and patients recevied either perioperative trastuzumab, a combination of perioperative lapatinib and trastuzumab, or standard care. Part 2 of EPHOS-B closed to recruitment in September 2015. Perioperative treatment consists of 11 days pre-operative treatment and further post-operative treatment, and participants will be followed up for 10 years.

Further information

Chief Investigator: Professor Nigel Bundred, University of Manchester/University Hospital of South Manchester NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: [email protected]

ISRCTN: 15004993

Sponsors: The Institute of Cancer Research and University of Manchester/University Hospital of South Manchester NHS Foundation Trust

Funding: Cancer Research UK (CRUK/08/002) and GlaxoSmithKline

Further information including recruitment progress is available from the following link:

UKCRN portfolio

Patient friendly information is available from the following link:

CancerHelp UK  

Publications and presentations

Bliss JM, Robison LE, Webster-Smith MF, Emson MA, Kilburn LS, Smith IE, Robertson J, Dowsett M, Bundred NJ, Cameron DA, Vidya R, Horgan K, Evans AA, Kokan JS, Pinhel I, A'Hern R; on behalf of the POETIC and EPHOS-B Trialists. A trial model for the future in the search for personalised medicine – the UK POETIC and EPHOS-B perioperative trials experience.  Cancer Res. 2011; 71(24 Suppl): Abstract number OT2-03-04.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.